Valspodar
- Generic Name
- Valspodar
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C63H111N11O12
- CAS Number
- 121584-18-7
- Unique Ingredient Identifier
- Q7ZP55KF3X
- Background
Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002912
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 640
- Registration Number
- NCT00003190
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Basophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- Drug: cytarabineBiological: aldesleukinOther: clinical observationDrug: daunorubicin hydrochlorideBiological: filgrastimDrug: etoposideOther: pharmacological studyDrug: valspodarDrug: busulfanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT00006363
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath